NAD+ vs B12 Injections

What Each Approach Does

Vitamin B12 is a cobalamin compound that serves as an essential cofactor in two enzymatic reactions: the conversion of methylmalonyl-CoA to succinyl-CoA and the remethylation of homocysteine to methionine. These reactions are critical for red blood cell formation, myelin synthesis, and one-carbon metabolism. In individuals with pernicious anemia or dietary deficiency, B12 injections restore normal hematopoiesis and resolve the neurological and hematological symptoms of deficiency. The fatigue relief in these cases is well-characterized and directly attributable to correcting the underlying biochemical defect.

NAD+ is nicotinamide adenine dinucleotide, a dinucleotide coenzyme that participates in over 500 enzymatic reactions. It functions as a primary electron carrier in the mitochondrial electron transport chain, shuttling electrons through complexes I through IV to drive oxidative phosphorylation and ATP synthesis. Beyond energy metabolism, NAD+ serves as a substrate for sirtuins (SIRT1-7), a family of deacetylases involved in genomic stability, mitochondrial biogenesis, and inflammatory regulation. It is also consumed by poly(ADP-ribose) polymerases (PARPs) during DNA damage repair. Tissue NAD+ levels decline measurably with age, and this decline has been linked to mitochondrial dysfunction, impaired cellular repair, and metabolic deterioration.

Where They Differ

B12 and NAD+ address fatigue through entirely separate biochemical axes. B12 corrects a nutritional gap. When serum cobalamin is low, supplementation restores normal methylation and erythropoiesis, and fatigue resolves as oxygen-carrying capacity and neurological function normalize. In individuals with adequate B12 levels, additional supplementation provides no demonstrated benefit for energy or cognition.

NAD+ operates at the level of mitochondrial metabolism and epigenetic regulation. Its decline with age is independent of nutritional B12 status and reflects a different category of metabolic change. Restoring NAD+ levels through precursors such as nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) aims to re-establish mitochondrial efficiency, activate sirtuin-dependent repair cascades, and counteract the metabolic signature of aging. These two interventions do not compete with each other. One addresses a vitamin deficiency; the other targets an age-associated coenzyme depletion that operates downstream of nutrient sufficiency.

Evidence Comparison

B12 injection therapy for deficiency-related fatigue is supported by decades of human clinical trials and is standard of care in hematology and primary care. The diagnostic and therapeutic pathway is well-established: low serum B12 or elevated methylmalonic acid confirms deficiency, and intramuscular cobalamin resolves symptoms with predictable kinetics. This is mature, high-quality evidence with clear clinical endpoints.

NAD+ precursor research is at an earlier stage. The 2018 Cell Metabolism review by Yoshino, Baur, and Imai documented the biological rationale for NMN and NR supplementation, drawing on extensive preclinical data showing restored NAD+ levels, improved mitochondrial function, and extended healthspan in aged animal models. Human pharmacokinetic studies have confirmed that oral NMN and NR safely raise blood NAD+ levels. However, long-term clinical outcome data in humans remains limited. The mechanistic case is strong and the safety profile is favorable, but the evidence base has not yet reached the level of large randomized controlled trials with hard clinical endpoints for fatigue or aging-related outcomes.

Who Might Consider Each

Individuals with documented B12 deficiency, malabsorption syndromes, or pernicious anemia have a clear clinical indication for B12 injection therapy. The intervention is well-characterized, widely available, and covered by standard medical practice. For individuals whose B12 levels are normal but who experience persistent fatigue, particularly in the context of aging or metabolic decline, NAD+ precursor therapy represents a mechanistically distinct option targeting mitochondrial and epigenetic pathways that B12 does not influence. Some individuals may benefit from both, as the two interventions are non-overlapping in their biochemical targets. This is a decision for you and your provider based on your specific labs, history, and goals.